Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

May 17, 2024

BUY
$9.26 - $31.31 $75,681 - $255,896
8,173 New
8,173 $128,000
Q3 2021

Jun 21, 2023

BUY
$9.26 - $31.31 $75,681 - $255,896
8,173 New
8,173 $129 Million
Q3 2020

May 24, 2024

BUY
$9.99 - $16.13 $8,721 - $14,081
873 Added 13.31%
7,433 $98.9 Million
Q3 2020

Jun 26, 2023

BUY
$9.99 - $16.13 $74,255 - $119,894
7,433 New
7,433 $98.9 Million
Q2 2020

May 24, 2024

BUY
$11.21 - $18.15 $73,537 - $119,063
6,560 New
6,560 $98.9 Million
Q2 2020

Jun 26, 2023

BUY
$11.21 - $18.15 $73,537 - $119,063
6,560 New
6,560 $98.9 Million
Q1 2020

Jul 12, 2023

BUY
$9.68 - $18.47 $63,500 - $121,163
6,560 New
6,560 $84 Million

Others Institutions Holding BYSI

About BeyondSpring Inc.


  • Ticker BYSI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,928,900
  • Market Cap $66.6M
  • Description
  • BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...
More about BYSI
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.